Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Alyson Haslam,Vinay Prasad +1 more
- Vol. 2, Iss: 5
TLDR
The estimated percentages of patients who are eligible for and who respond to checkpoint inhibitor drugs are higher than reported estimates for drugs approved for genome-driven oncology but remain modest.Abstract:
Importance Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number of hitherto intractable tumor types. Objective To estimate the percentage of patients with cancer in the United States who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration (FDA). Design, Setting, and Participants Retrospective cross-sectional study performed from June 2018 through October 2018 using publicly available data to determine (1) demographic characteristics of patients with advanced or metastatic cancer, (2) FDA data on checkpoint inhibitors approved from January 2011 through August 2018, (3) measures of response from drug labels, and (4) published reports estimating the frequency of various inclusion criteria. Main Outcomes and Measures The estimated percentages of US patients with cancer who are eligible for and who respond to immunotherapy checkpoint inhibitor drugs, by year. Results Six checkpoint inhibitor drugs were approved for 14 indications between March 25, 2011, and August 17, 2018. The estimated percentage of patients with cancer who were eligible for checkpoint inhibitor drugs increased from 1.54% (95% CI, 1.51%-1.57%) in 2011 to 43.63% (95% CI, 43.51%-43.75%) in 2018. The percentage of patients with cancer estimated to respond to checkpoint inhibitor drugs was 0.14% (95% CI, 0.13%-0.15%) in 2011 when ipilimumab was approved for unresectable or metastatic melanoma and increased to 5.86% (95% CI, 5.80%-5.92%) by 2015. By 2018, the estimated percentage of responders increased to 12.46% (95% CI, 12.37%-12.54%). Conclusions and Relevance The estimated percentages of patients who are eligible for and who respond to checkpoint inhibitor drugs are higher than reported estimates for drugs approved for genome-driven oncology but remain modest. Future research should explore biomarkers to maximize the benefit of immunotherapy among patients receiving it.read more
Citations
More filters
Journal ArticleDOI
Systemic immunity in cancer
TL;DR: In this paper, the authors comprehensively outline the current knowledge of systemic immunity in cancer, and show that new immune responses in individuals burdened with tumours are compromised even beyond the TME.
Journal ArticleDOI
Cytotoxic CD8 + T cells in cancer and cancer immunotherapy
TL;DR: Advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, are summarized and possible implications for future cancer treatment are discussed.
Journal ArticleDOI
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
TL;DR: The authors describe the potential of nanomedicines to normalize the tumour microenvironment, thus overcoming this immunosuppressive barrier and enabling greater numbers of patients to respond to immune-checkpoint inhibition.
Journal ArticleDOI
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
Enrico Ammirati,Maria Frigerio,Eric Adler,Cristina Basso,David H. Birnie,Michela Brambatti,Michela Brambatti,Matthias G. Friedrich,Karin Klingel,Jukka Lehtonen,Javid Moslehi,Patrizia Pedrotti,Ornella Rimoldi,Heinz-Peter Schultheiss,Carsten Tschöpe,Leslie T. Cooper,Paolo G. Camici +16 more
TL;DR: This research presents a novel probabilistic approach that allows us to assess the importance of knowing the carrier and removal status of canine coronavirus, as a source of infection for other animals.
Journal ArticleDOI
Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque.
Zsofia D. Drobni,Zsofia D. Drobni,Raza M. Alvi,Jana Taron,Amna Zafar,Sean P. Murphy,Paula K. Rambarat,Rayma C. Mosarla,Charlotte E. Lee,Daniel A. Zlotoff,Vineet K. Raghu,Sarah Hartmann,Hannah K Gilman,Jingyi Gong,Leyre Zubiri,Ryan J. Sullivan,Kerry L. Reynolds,Thomas Mayrhofer,Lili Zhang,Udo Hoffmann,Tomas G. Neilan +20 more
TL;DR: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids.
References
More filters
Journal ArticleDOI
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman,Laurence Zitvogel,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Guido Kroemer +5 more
TL;DR: The immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters.
Journal ArticleDOI
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
TL;DR: The roles of VEGF and ANG2 are outlined, and ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes are suggested, and avenues of future research are highlighted.
Journal ArticleDOI
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun Vasant Balar,Daniel Castellano,Peter H. O'Donnell,Petros Grivas,Jacqueline Vuky,Thomas Powles,Elizabeth R. Plimack,Noah M. Hahn,Ronald de Wit,Lei Pang,Mary J. Savage,Rodolfo F. Perini,Stephen Michael Keefe,Dean F. Bajorin,Joaquim Bellmunt +14 more
TL;DR: First-line pembrolizumab has antitumour activity and acceptable tolerability in cisplatin-ineligible patients with urothelial cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities.
Journal ArticleDOI
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
TL;DR: Although the number of patients eligible for genome-driven treatment has increased over time, these drugs have helped a minority of patients with advanced cancer and should be pursued to accelerate progress in precision oncology.
Journal ArticleDOI
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.
TL;DR: The mechanisms of action, side effects, and patient and family management and education concerns are discussed to provide oncology nurses up-to-date information relevant to caring for cancer-affected patients treated with immune checkpoint inhibitors.
Related Papers (5)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin,James Larkin +33 more
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more